Loretta Nastoupil, MD

home / authors / loretta-nastoupil-md

Articles

Dr Nastoupil on the Investigation of Liso-Cel in Relapsed/Refractory Follicular Lymphoma

September 8th 2023

Loretta J. Nastoupil, MD, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.

Gina Mauro of OncLive and Loretta Nastoupil, of The University of Texas MD Anderson Cancer Center

Pivotal Data in NHL and Pediatric Cancers at ASH 2021: Insight From Drs. Loretta Nastoupil and Michael Pulsipher

Gina Mauro;Loretta Nastoupil, MD;Michael Pulsipher, MD

December 12th 2021

OncLive speaks with Dr. Loretta Nastoupil on some exciting non-Hodgkin lymphoma studies and Dr. Michael Pulsipher on some intriguing pediatric cancer research.

Loretta J. Nastoupil, MD, discusses logistical considerations for CAR T-cell therapy in patients with diffuse large B-cell lymphoma.

Dr. Nastoupil on Logistical Considerations for CAR T-Cell Therapy in DLBCL

Loretta Nastoupil, MD

February 5th 2021

Loretta J. Nastoupil, MD, discusses logistical considerations for CAR T-cell therapy in patients with diffuse large B-cell lymphoma.

Loretta J. Nastoupil, MD, discusses challenges faced with CAR T-cell therapy in patients with diffuse large B-cell lymphoma.

Dr. Nastoupil on Challenges Faced With CAR T-Cell Therapy in DLBCL

Loretta Nastoupil, MD

February 3rd 2021

Loretta J. Nastoupil, MD, discusses challenges faced with CAR T-cell therapy in patients with diffuse large B-cell lymphoma.

Combined Radiation Therapy and Checkpoint Inhibition in Lymphoma: A Case Report and Brief Review

Chelsea C. Pinnix, MD, PhD;Chul S. Ha, MD;Yasuhiro Oki, MD;Sattva Neelapu, MD;Loretta Nastoupil, MD;Louis S. Constine, MD

March 31st 2018

The emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.